Applied NeuroSolutions inks drug pact with Lilly

Applied NeuroSolutions has inked a development deal with Eli Lilly for new drugs to treat Alzheimer's. Applied NeuroSolutions gains $2 million up front along with research funds. And it stands to earn between $10 million and $20 million for each new therapy that is developed. Applied NeuroSolutions has been investigating the proteins that gather on neurons in Alzheimer's cases.

- see this release on the development deal

Related Article:
Applied NeuroSolutions appoints Ellen R. Hoffing as president and CEO. Report